Stay updated with breaking news from Lori Leslie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.
Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.
Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.
The driver of the dump truck jumped out of the vehicle before the collision.
Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d...